01799nas a2200421   4500000000100000008004100001260001300042653001000055653001200065653002600077653001800103653002100121653000900142653001100151653001200162653000900174653000900183653001600192653001700208653002500225653001500250653000900265653002200274100001600296700001300312700001500325700001600340700001300356700001500369700001400384700001300398245006900411856007300480300001100553490000700564520079200571022001401363       2008                            d  c2008 Sep10aAdult10aAnimals10aAnti-Bacterial Agents10aAza Compounds10aFluoroquinolones10aFoot10aHumans10aleprosy10aMale10aMice10aMiddle Aged10aMoxifloxacin10aMycobacterium leprae10aQuinolines10aSkin10aTreatment Outcome1 aPardillo FE1 aBurgos J1 aFajardo TT1 aDela Cruz E1 aAbalos R1 aParedes RM1 aAndaya CE1 aGelber R00aPowerful bactericidal activity of moxifloxacin in human leprosy.  uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2533472/pdf/1162-07.pdf  a3113-70 v523 a<p>In a clinical trial of moxifloxacin in eight multibacillary leprosy patients, moxifloxacin proved highly effective. In all trial patients, a single 400-mg dose of moxifloxacin resulted in significant killing (P <or= 0.006) of Mycobacterium leprae, ranging from 82% to 99%, with a mean of 91%. In all instances, no viable bacilli were detected with an additional 3 weeks of daily therapy, this observed rapid bactericidal activity being matched previously only by rifampin. On moxifloxacin therapy, skin lesions cleared exceedingly rapidly with definite improvement observed consistently after eight doses and progressive resolution continuing for the 56 days of the trial. Side effects, toxicities, and laboratory abnormalities were mild, not requiring discontinuation of therapy.</p>  a1098-6596